文献速递糖尿病

利拉鲁肽对心率及心率变异性的影响:一项随机、双盲、安慰剂对照交叉研究

Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
PubMed 文献 · Diabetes Care · 2016-10-19

在超重且新诊断2型糖尿病合并稳定冠心病的患者中,采用双盲安慰剂对照12+12周交叉设计,利拉鲁肽较安慰剂降低心率变异性指标SDNN和RMSSD、降低高频功率并升高平均心率和夜间心率,尽管体重和代谢指标改善。

要点

  • 利拉鲁肽较安慰剂降低SDNN(-33.9 ms,P<0.001)和RMSSD(-0.3 log-ms,P=0.025)。
  • 利拉鲁肽较安慰剂升高平均心率(8.1次/分,P=0.003)和夜间心率(6.3次/分,P=0.026)。
  • 利拉鲁肽较安慰剂降低高频功率(-0.7 log-ms2,P=0.026),低频/高频比值无变化。

核心结论

  • 在超重且新诊断2型糖尿病合并稳定冠心病的患者中,利拉鲁肽尽管显著减轻体重并改善代谢参数,仍升高心率并降低心率变异性。
  • 夜间心率升高伴随副交感活性参数降低,提示利拉鲁肽可能影响交感迷走平衡。

研究设计与样本

  • 随机、双盲、安慰剂对照12+12周交叉研究,在二甲双胍背景治疗基础上给予利拉鲁肽或安慰剂。
  • 共27名超重且新诊断2型糖尿病合并稳定冠心病的患者纳入分析。

主要发现

  • 与安慰剂相比,利拉鲁肽降低SDNN(-33.9 ms;P<0.001,配对分析)。
  • 与安慰剂相比,利拉鲁肽降低RMSSD(-0.3 log-ms;P=0.025)。
  • 与安慰剂相比,利拉鲁肽升高平均心率(8.1次/分;P=0.003)、日间心率(5.7次/分;P=0.083)和夜间心率(6.3次/分;P=0.026)。
  • 多变量回归分析中,校正代谢和心率变化后,SDNN下降仍显著。
  • 与安慰剂相比,利拉鲁肽降低高频功率(-0.7 log-ms2;P=0.026),低频/高频比值无变化。

关键数值与推荐

  • SDNN变化:利拉鲁肽较安慰剂-33.9 ms(P<0.001,配对分析)。
  • RMSSD变化:利拉鲁肽较安慰剂-0.3 log-ms(P=0.025)。
  • 平均心率变化:利拉鲁肽较安慰剂+8.1次/分(P=0.003);日间心率+5.7次/分(P=0.083);夜间心率+6.3次/分(P=0.026)。
  • 高频功率变化:利拉鲁肽较安慰剂-0.7 log-ms2(P=0.026);低频/高频比值无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Reduced heart rate variability (HRV) and increased heart rate (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, and studies have suggested that they may reduce HRV. We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study. SD of beat-to-beat (NN) intervals (SDNN) was assessed by 24-h Holter monitoring as a measure of HRV. Diurnal HR variation and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF) and low-frequency (LF) power were assessed. RESULTS: Compared with placebo, liraglutide decreased SDNN in 27 subjects (-33.9 ms; P < 0.001, paired analysis); decreased RMSSD (-0.3 log-ms; P = 0.025); and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026). In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes. Liraglutide reduced HF power (-0.7 log-ms2; P = 0.026) without any change in LF/HF ratio. CONCLUSIONS: In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters. The increase in nightly HR in conjunction with a decrease in parameters of parasympathetic activity suggests that liraglutide may affect sympathovagal balance.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kumarathurai P, Anholm C, Larsen BS, et al. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. 2016. PMID: 27797930. doi:10.2337/dc16-1580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。